The tide of medical and health innovation is surging, and high-quality innovation projects are the core driving force of industry development and the focus of capital and industry cooperation.In this phase, eight high-value medical innovation projects are gathered, covering eight core areas, including vaccines and antibodies, RNA delivery, CGT cdmo, to accurately match clinical rigid needs and industrial needs.

Now it is open to investment institutions, pharmaceutical enterprises and other partners to jointly explore industry opportunities and expand new space for the medical and health industry.

---

The following is the introduction of medical assets in this period:

1、 Vaccine _; infectious disease vaccine and antibody research and development platform

This is an innovative platform company focusing on high-value infectious disease vaccines and antibodies. Its core highlights are its top-level R & D and transformation capabilities, differentiated underlying technology platforms, mid-term clinical core assets and advanced industrialization layout.

The company’s core team originated from the first tier of domestic infectious disease vaccine and antibody research and development. It has led the research and development of the world’s first approved emergency use neocoronal recombinant protein vaccine, and achieved the international authorization of neocoronal therapeutic antibody. The full link from scientific discovery to commercial landing has been verified in practice, and has mature clinical application, registration and approval, industrial cooperation and commercial transformation strength.

At the technical level, relying on structural biology, single-b-cell sequencing, epitope analysis and AI aided design, we built a self-research platform, focused on the rational design of antigen and antibody screening of highly difficult viral targets, overcome the industrial problems such as conformational stability, epitope retention, immune risk control that are difficult to break through in traditional research and development, and formed deep technical barriers.

At the same time, high barrier pipelines such as mRNA vaccines, rare virus vaccines and broad-spectrum bispecific antibodies were laid out to verify the platform’s replicability and build the second growth curve in the medium and long term.

By the end of 2024, the company has built its first industrialization base with a total investment of 200million yuan, a building area of 13000 square meters, and an annual design capacity of 10million doses. It has made up for the lack of capacity in advance, laying a solid hardware foundation for clinical promotion, product listing and commercial large-scale supply.

---

2、 Exosomal \u RNA delivery and clinical exosomal drugs

The company focuses on the central nervous system (CNS) drug delivery field, builds a double-layer core layout of “natural exosomal drug + RNA delivery platform”, takes into account short-term clinical transformation and long-term technical barriers, and is a high-quality target with both innovation and commercialization potential.

The core layout is divided into two parts: the front-end focuses on the research and development of natural exosomal drugs, covering multiple scenes such as severe pulmonary inflammation, acute exacerbation of COPD, stroke, Alzheimer’s disease, and some directions have accumulated human cases and IIT data, which has a clear basis for clinical promotion; The back-end focuses on building an engineered biological vesicle mediated central RNA delivery chassis to specifically solve the core pain points of the industry, such as the difficulty of RNA drugs crossing the blood-brain barrier, the insufficient distribution in the brain, and the inconvenience of long-term drug administration.

The platform has outstanding core advantages, can be compatible with siRNA, mRNA and other loads, and has the capacity of multi RNA co loading and long fragment loading. Clinical data show that its vesicle loading capacity is high, the functional brain knockdown effect is 40% – 60%, and the neuronal delivery ability is strong; .

At present, the drug terminal has completed early human validation in the direction of severe inflammation and heart failure, and CMC and production process are promoting overseas cooperation and authorization negotiations; The platform aims at the high barrier central RNA drug track, which can support the dual development of self-research and foreign cooperation. The company plans to promote clinical research and development, GMP capacity construction and RNA delivery platform expansion through a round of financing of 50million-100million yuan, so as to achieve a two-way breakthrough in short-term transformation and long-term layout.

---

3、 Cell and gene therapy _; global compliant production and commercialized enabling platform

The core asset of this project is a contract research, development and production organization (cdmo) that focuses on the field of cell and gene therapy (CGT). It focuses on providing one-stop GMP production and application support from plasmids, viral vectors to cell therapy products for global CGT innovative pharmaceutical enterprises. It is the key infrastructure for the CGT industry to move from laboratory to commercialization. It is different from the traditional cdmo pure capacity expansion mode, and is driven by the “CMC capacity + commercialization ecology” dual engine development.

At the technical level, the core barrier was built, and the chromatography free plasmid purification platform was independently developed, eliminating the time-consuming chromatography steps, reducing the process time by 50%, and increasing the proportion of supercoiles to more than 95%; Optimize the virus vector process, so that the AAV downstream full shell rate can reach 90% – 95%, and have a compliant HEK293 production cell bank, which can support the declaration in China, the United States and Europe, and also reduce customer compliance and capital pressure in a flexible mode. .

The client has served a number of CGT head enterprises at home and abroad, covering gene therapy, car-t and other cutting-edge directions, building a collaborative ecosystem of “technology + supply chain + channel”, leading in customer stickiness and order conversion rate. The profit side relies on process optimization to achieve a high gross margin, forming a two-tier revenue structure of “early R & D orders + commercialized large-scale orders”, with stable cash flow. The layout of the Sino US dual base can undertake global orders and disperse market risks.

At present, the compound annual growth rate of the global CGT cdmo market is more than 24%, and the scale is expected to exceed 30billion US dollars in 2032. Under the trend of accelerating the industry to go to sea and the supply chain to pursue compliance and efficiency, the target has become a high-quality option for the layout of CGT manufacturing infrastructure by virtue of its technology, efficiency and customer ecological advantages, and has broad investment and financing value.

---

4、 Intelligent diagnosis and treatment _ai muscle bone ultrasound diagnosis and treatment platform

The project focuses on the AI muscle bone ultrasound track, creating an integrated diagnosis and treatment solution of software algorithm + ultrasound terminal + treatment consumables, effectively reducing the dependence of muscle bone ultrasound on the clinical experience of doctors, and complementing the shortcomings of standardized diagnosis and treatment in grass-roots and specialized institutions. Musculoskeletal ultrasound is widely used in orthopedics, pain department, rehabilitation department, sports medicine and other departments, but traditional imaging highly relies on the ability of doctors to operate and interpret, which has long restricted the large-scale popularization of grassroots. The project relies on AI image recognition and intelligent analysis technology to realize automatic recognition of muscle and bone structures, intelligent labeling and quantitative analysis of lesions, significantly improve the diagnostic efficiency, and assist the clinical development of precise treatment plans.

. Relying on the clinical data and academic co construction system of top three hospitals in the head, 310 hospitals have been settled, 296 equipment have been shipped in total, and 6 professional training bases have been laid out, forming a positive closed loop of clinical data AI model iteration physician training equipment promotion, and building a triple barrier of data, academic and channel.

The annual demand for diagnosis and treatment of musculoskeletal diseases in China has reached 500million people. With the accelerated aging and the rapid development of sports medicine and rehabilitation, the demand for accurate diagnosis and treatment of musculoskeletal diseases has continued to expand. Compared with large-scale imaging equipment, musculoskeletal ultrasound has the advantages of low cost, bedside operability, real-time dynamic imaging, and broad sinking space of the base.

The project adopts the compound business model of equipment sales + software subscription authorization + PrP treatment consumables, and uses hardware installation to drive software and consumables repurchase, forming a sustainable cash flow. The medium-term goal is to achieve the installation of more than 3000 units, long-term penetration into the 100000 unit market, clear business model and solid foundation for landing. It is a high-quality investment asset of AI medical imaging base sinking track.

---

5、 Cell therapy _; universal IPSC cell therapy platform

The company is equipped with a 4000 square meter research and development site and a 1000 square meter GMP cell preparation workshop. It has deeply integrated the blood transfusion Institute of the medical college, West China Hospital, Sichuan Provincial People’s Hospital and overseas top IPSC scientific research resources, and built a complete technical system from cell traceability, functional cell development to clinical transformation and application. Relying on the advantages of IPSC technology, the core of the platform can realize unified cell sources, controllable quality, large-scale mass production, and highly adapt to the development logic of universal off the shelf cellular drugs.

The layout of technical patents is perfect, with a total of 18 related patents, including 10 invention patents, covering key technical links such as IPSC, MSC, Treg, NK and organoid culture preparation. The pipeline is promoted in multi-point coordination, crossing high potential tracks such as alopecia, Alzheimer’s disease, liver cancer, etc; Among them, IIT clinical research has been carried out in Sichuan Provincial People’s Hospital for the indications of hair loss, and animal experiments have verified that the effect of increasing hair density is significant; Alzheimer’s disease precisely matches the needs of the aging population in China. The liver cancer pipeline is arranged around the GPC3 target for universal cell therapy, with clear growth space.

At the industry level, the global IPSC cell therapy has entered the accelerated industrialization stage, overseas products have been approved, and a number of pipelines have entered the mid to late clinical stage. Domestic capital will continue to concentrate on the racetrack from 2025 to 2026. . The project relies on mature technology platform, multi pipeline landing foundation and its own GMP production capacity reserves, and has both cutting-edge technical barriers and short-term clinical transformation value. It is a high-quality investment target with high certainty for the cell therapy track.

---

6、 Delivery platform _; central nervous system nucleic acid nano delivery platform

The project focuses on the high barrier drug delivery track of the central nervous system, relies on nucleic acid nanostructured particles to build a programmable universal delivery platform, which can be compatible with DNA, RNA, protein and small molecule loads, and directly hits the core pain points of the industry such as low delivery efficiency, weak load adaptability, and difficult immunogenicity control in the deep brain and spinal cord.The platform uses short strand DNA as the basic raw material, and realizes tissue targeted and selective delivery through shape, structure and size programmable design. It has both in vivo degradability and biosafety, and is suitable for complex central indications such as neurodegenerative diseases and brain tumors. At present, multiple pipelines for brain delivery, spinal cord delivery, brain tumor and triple negative breast cancer have been laid out, and the underlying platform + self-developed pipeline + joint development + external authorization diversified business model has been built, with clear commercialization path.

The platform has outstanding core advantages. The distribution ability of deep brain parenchyma has been verified head to head. It can penetrate the brain surface to achieve effective enrichment of deep tissue, far exceeding the attenuation distribution characteristics of traditional technology; . At the same time, it is compatible with multiple types of loads, which can not only support the development of self-developed CNS pipelines, but also serve as a general efficiency module to externally empower cooperative assets.

The core team has been deeply involved in the field of nucleic acid self-assembly and delivery, with profound academic achievements. It undertakes national key research and development programs, the National Natural Science Foundation and other national projects, and has the strength of continuous technology iteration and scientific research transformation. The project is currently in a critical pre clinical stage, the underlying mechanism has been completely constructed, the key pipelines have been verified in rodents and non-human primates, and the first central indication has produced clear efficacy data.

Central drug delivery has always been a high-value rigid demand track for innovative drug research and development. The platform has formed a complete early verification loop and is expected to grow into a general base chassis in the central delivery field. In the follow-up, we can promote the valuation improvement through self-developed pipelines, and can also rely on cooperative development and technology authorization to continuously expand the commercial value, which has a very strong industrial transaction extension space and long-term investment value.

---

7、 Innovative drug \u pan RAS (on) molecular glue small molecule platform

The project focuses on the race track of ras mutations driving solid tumors. The core asset is Pan RAS (on) molecular glue small molecule inhibitors, which accurately layout multiple Ras driven tumors and drug resistance clinical scenarios. .

The pipeline mainly focuses on the field of solid tumors, and has the clear potential to combine with Prmt5, mat2a, PD-1 and other target drugs. It can cover indications with high unmet clinical needs such as pancreatic cancer and non-small cell lung cancer, and has a broad space for commercialization. At present, the project has been approved by ind and is in the key stage of clinical application and enrollment. It shows significant dose and efficacy advantages in comparison with competing products in the same target.

The CDX model data showed that in KRAS G12D, G12V pancreatic cancer and colorectal cancer models, only about 1/3 to 1/8 dose of rmc-6236 was required to achieve equivalent tumor inhibition effect. Tumor retraction has been observed at the dose of 3mg/kg, and the therapeutic dose safety performance was good. The pharmacokinetics in rats and beagles was linear and could predict the exposure characteristics, which was convenient for clinical dose planning; The skin and intestinal exposure are lower in tissue distribution, which is expected to significantly improve the short board of tolerance to similar drugs such as rash and diarrhea.

Relying on the self-developed small molecule R & D platform, the project synchronously derived candidate molecules with ADC loading potential. The cell activity and in vivo exposure were better than the benchmark varieties, leaving room for subsequent external authorization and product portfolio layout. Since its establishment in 2021, the enterprise has built a complete R & D system from drug discovery to clinical development, with 4 clinical stages and 6 pre clinical pipelines under research, and its assets have been authorized to land.

---

8、 Ivd_mass spectrometry detection technology

The project directly targets the domestic clinical mass spectrometry industry, which has been monopolized by imports for a long time and has a localization rate of less than 1%. Its core asset is the independently developed medical triple quadrupole liquid chromatography-mass spectrometry system, coupled with a full coverage kit matrix, which is the core target of domestic replacement of high-end clinical mass spectrometry instruments.

. Without upgrading the hardware, the detection sensitivity of some metabolites can be improved by tens to thousands of times, and hundreds of metabolites can be quantified in 15 minutes, with significant advantages in high throughput and detection performance.

The progress of product implementation is solid. At present, 13 or more clinical mass spectrometry kits have completed nmpa class I filing and listing, covering amino acids, vitamins, bile acids, neurotransmitters and other mainstream detection categories, and have been stationed in many grade III and grade A hospitals to carry out clinical detection services; Medical triple quadrupole mass spectrometer is accelerating the application for medical device registration, and the evidence is about to be obtained. The project adopts the integrated mode of instrument platform + supporting reagents + professional detection services, which effectively solves the pain points of industries such as high procurement and maintenance costs of imported equipment, weak reagent adaptability, and supply chain being controlled by people.

The domestic clinical mass spectrometry market has maintained a compound annual growth rate of nearly 10%. In 2025, the size of the triple quadrupole segment market is about 5.6 billion yuan, and there is a broad space for domestic substitution. The business model is clear, taking instrument sales and financial leasing as short-term income, and relying on Kit continuous consumables and cloud services to form a long-term stable cash flow, with a focus on the laboratory and third-party medical laboratories of the third-class hospitals.

The team is composed of national leading metabolomics experts, domestic founders of mass spectrometry and industry executives with experience in commercialization of large varieties, and runs through the whole chain from hardware R & D, methodology development to clinical commercialization. .

This time, eight high-quality medical and health innovation assets were gathered, focusing on cutting-edge technological breakthroughs, covering eight popular tracks, including vaccine antibodies, exosomal RNA delivery, CGT cdmo, AI intelligent diagnosis and treatment, IPSC cell therapy, central nucleic acid delivery, RAS innovative drugs, and clinical mass spectrometry IVD.

---

All projects have hard core technical barriers, clear clinical transformation progress, mature business model and broad domestic substitution space, which can accurately match the diversified needs of institutional investment and financing, industrial strategic mergers and acquisitions, cross-border BD cooperation and in-depth commercialization.

Cooperation docking channel!!!!

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.